首页> 外国专利> MARKER AND DIAGNOSTIC METHOD FOR NON-INVASIVE DIAGNOSIS OF MYOCARDIAL INFARCTION

MARKER AND DIAGNOSTIC METHOD FOR NON-INVASIVE DIAGNOSIS OF MYOCARDIAL INFARCTION

机译:心肌梗死的非侵入性诊断的标记和诊断方法

摘要

Disclosed are a marker and diagnostic method for non-invasive diagnosis of myocardial infarction. Using second-generation sequencing and QPCR methods, it was found that there are significant differences in the expression of ING1, RAE1, DOCK10, KDSR, IVD, and MAEA in the blood of normal and myocardial infarction patients; that is, whether the subject has myocardial infarction can be determined by means of detecting the expression of ING1, RAE1, DOCK10, KDSR, IVD, and MAEA in the blood. According to the relevance between the two above, a test kit for diagnosing myocardial infarction was developed; the test kit performs myocardial infarction diagnosis by means of detecting the expression of ING1, RAE1, DOCK10, KDSR, IVD, and MAEA. The described diagnostic test kit can be used for early diagnosis of diseases, and has broad prospects for application in clinical practice.
机译:公开了用于心肌梗塞的非侵入性诊断的标记物和诊断方法。使用第二代测序和QPCR方法,发现正常和心肌梗死患者血液中ING1,RAE1,DOCK10,KDSR,IVD和MAEA的表达存在显着差异。也就是说,可以通过检测血液中ING1,RAE1,DOCK10,KDSR,IVD和MAEA的表达来确定受试者是否患有心肌梗塞。根据以上两者之间的相关性,开发了用于诊断心肌梗塞的测试套件。该测试套件通过检测ING1,RAE1,DOCK10,KDSR,IVD和MAEA的表达来进行心肌梗塞诊断。所描述的诊断测试试剂盒可用于疾病的早期诊断,并在临床实践中具有广阔的应用前景。

著录项

  • 公开/公告号WO2020007270A1

    专利类型

  • 公开/公告日2020-01-09

    原文格式PDF

  • 申请/专利权人 BEIJING MEDINTELL BIOMED CO. LTD;

    申请/专利号WO2019CN94268

  • 发明设计人 YANG CHENGGANG;LI SHUGUANG;

    申请日2019-07-01

  • 分类号C12Q1/6886;

  • 国家 WO

  • 入库时间 2022-08-21 11:13:56

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号